购物车
- 全部删除
- 您的购物车当前为空
Lesinurad (RDEA594) 是URAT1和OAT 抑制剂。Lesinurad 用作肾转运蛋白OAT1 和OAT3 的底物,Km 分别为 0.85 和 2 μM。
Lesinurad (RDEA594) 是URAT1和OAT 抑制剂。Lesinurad 用作肾转运蛋白OAT1 和OAT3 的底物,Km 分别为 0.85 和 2 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 313 | 现货 | |
10 mg | ¥ 452 | 现货 | |
25 mg | ¥ 715 | 现货 | |
50 mg | ¥ 1,190 | 现货 | |
100 mg | ¥ 1,890 | 现货 | |
200 mg | ¥ 2,850 | 现货 | |
500 mg | ¥ 4,630 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 387 | 现货 |
产品描述 | Lesinurad (RDEA594) is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad has had a limited clinical use but has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury. |
靶点活性 | OAT3:2 µM (Km), OAT1:0.85 µM (Km) |
体外活性 | Lesinurad 以20倍于大鼠URAT1(rURAT1)的高效力抑制人体URAT1(hURAT1)的尿酸运输活动,其IC50分别为3.36和74.84 μM。Lesinurad通过涉及关键残基Phe365[1]的相互作用来抑制hURAT1。 |
体内活性 | Lesinurad (RDEA594) 相比于其前体药物RDEA806展现了更佳的药动学特性。Lesinurad的100 mg剂量所展现的药理作用,相当于300 mg至800 mg RDEA806单剂量所产生的效果[2]。 |
细胞实验 | Lesinurad is solubilized in DMSO and stored, and then diluted with appropriate media before use[1]. Validated oocytes, HEK293, MDCK-II, Caco-2 or MDCK-MDR1 cell systems are used to study the interaction of Lesinurad with membrane transporters localized to the kidney (OAT1, OAT3, OCT2, MATE1, and MATE2K) or liver (P-gp, BCRP, OATP1B1, OATP1B3, and OCT1). Xenopus laevis oocytes are injected with OAT1 or OAT3 cRNA or control (water) while HEK293 cells are stably transfected with MATE1, MATE2K, or vector and MDCK-II cells with hOATP1B1, hOATP1B3, hOCT1, hOCT2, or vector. The MDCKII cell line is stably transfected with the human MDR1 gene to create a P-gp cell line. The interaction of Lesinurad with BCRP relied on the endogenous expression in Caco-2 cells. All cells are cultured with growth medium according to standard methodology. In order to determine whether Lesinurad is a substrate for a transporter, cells are incubated with [14C]-labeled Lesinurad at various concentrations and the amount of Lesinurad taken up by the cells determined by subtracting the uptake in vector cells from that in the transfected cells. The uptake of a [3H]-labeled known substrate of the transporter served as the positive control. Inhibition of a transporter by Lesinurad is determined by incubating cells with a fixed concentration of [3H]-labeled known substrate and various concentrations of unlabeled Lesinurad. Inhibition by a known inhibitor of each transporter served as the positive control. Cells are incubated for the appropriate amount of time. All reactions are terminated by the addition of ice-cold medium. The cells are then rinsed with medium and lysed[1]. |
别名 | RDEA594, 雷西那德, 来司诺雷 |
分子量 | 404.28 |
分子式 | C17H14BrN3O2S |
CAS No. | 878672-00-5 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (123.68 mM) Ethanol: 50 mg/mL (123.7 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.